Reference Laboratory
From routine diagnostics to selected specialty measurement. Explore the methods, the specimens and the questions behind a result.
The value of a high-precision reference laboratory
A result can inform diagnosis, help monitor a chronic condition or focus a treatment discussion. Its value depends on the right target, a suitable specimen, a qualified method and interpretation in the context of the person.
The proposed specialty menu includes targeted steroid mass spectrometry, elemental speciation and selected lipidomic measurements. Each addresses a defined analytical question that a broader panel may leave unresolved.
Targeted mass spectrometrySpecimen requirements, calibration, measurement limits and reference context belong with a result. Explore how detection, quantification and uncertainty affect the question a clinician can answer.
Explore measurement qualityFollow-up is more informative when method, units, timing and collection conditions can be compared. The Beyond vision connects laboratory context with care and the developing Medical OS record.
Connect the evidenceThe catalogue also includes elemental speciation, environmental biomonitoring, specialty lipid measurements and mitochondrial-method research, each with its own status. General interpretation background: National Library of Medicine.
Specialized questions / Specialized methods
The ambition is a reference laboratory that connects dependable routine testing with selected advanced methods. Explore what each can add, the questions it can help investigate, and its place in the Beyond roadmap.
High-resolution accurate-mass analysis for proteomics and molecular research.
Manufacturer reference ↗Trapped ion mobility and mass spectrometry provide complementary dimensions for proteomics research.
Manufacturer reference ↗9 method families / select a question to explore
Whole genome sequencing can investigate a broad range of genetic variants. Coverage, variant type, interpretation quality and the clinical question determine what a result can resolve. It does not identify every genetic cause.
Specialist assessment, phenotype review and genetic counseling guide test selection and follow-up.
Digital PCR partitions a sample to quantify selected DNA targets. A liquid-biopsy application needs validation for its target, specimen and intended use; an instrument’s sensitivity alone does not make a screening test reliable.
A negative result may reflect biology or assay limitations. Indication-specific specialist interpretation remains essential.
Validated molecular methods can identify selected bacterial, fungal or parasitic targets, sometimes to species level. The specimen, assay coverage, contamination controls and reference database determine what can be detected and distinguished.
Detection may represent infection, colonization, contamination or residual DNA. It does not by itself establish the cause of chronic inflammation; no assay identifies every species.
For selected gene–drug pairs, pharmacogenomic evidence can inform medication choice or dosing. Kidney and liver function, interactions, prior response and the treatment indication still matter.
The proposed care model combines a qualified result with clinician review, rather than selecting a treatment from genetics alone.
High-resolution accurate-mass analysis can help distinguish molecular features in complex samples. Protein and metabolite investigations require appropriate separation, calibration, identification criteria and quality controls.
Discovery findings and clinically validated measurements have different uses. Each proposed clinical assay needs its own performance evidence.
ICP-MS can measure selected elements at trace levels. Coupling a separation method can help distinguish chemical species, which may have different biological meaning. Collection materials and contamination control are critical.
Interpretation depends on the element, specimen, timing and exposure history. A detected metal is not automatically evidence of toxicity.
Single-cell ICP-MS can investigate elemental content and variability across individual cells. This is a research direction distinct from a routine whole-blood or urine metals test.
Transport efficiency, cell integrity, event detection and suitable reference materials must be characterized before interpreting a biological difference.
The roadmap considers complementary GC×GC–TOF MS, GC–VUV and high-performance ion chromatography–Orbitrap approaches. VUV spectroscopy and mass spectrometry provide different evidence about a separated compound.
These are separate method families; any proposed VUV/GC×GC/TOF or VUV/HPIC/Orbitrap configuration needs a defined design and validation. They are not presented as one established clinical assay.
Particle size, polymer identity, collection materials and contamination controls affect measurement. Methods and interpretation are still developing; a result cannot currently be treated as a validated personal disease-risk score.
The program is a research proposal, with no promised diagnosis, removal treatment or improvement in clinical outcomes.
What makes a measurement valuable?
Accuracy concerns closeness to a reference; precision concerns agreement between repeated measurements. A lower limit of detection can reveal smaller quantities, while a quantification limit addresses when a numerical result is sufficiently reliable. Each is method- and specimen-specific. Routine assays can be highly precise; specialized testing adds value when it answers an unresolved question.
Measurement terminology / NIST ↗The roadmap distinguishes planned pathways, proposed expansion and research. Instrument references do not imply manufacturer partnership, Beyond ownership, clinical approval or availability. See current program status.
Your question comes first
Start with what matters to you. Connect a question to the care pathways and measurements behind it.
Three related pathways. Select a record to inspect its scope.
Connect lipid measurements with blood pressure, history and a care pathway. Each record explains its purpose and current status.
Connect properly obtained measurements with medication review and an agreed follow-up plan.
Bring family history, lipid results and treatment context into a focused cardiovascular discussion.
Routine and selected specialty lipid measurements connected to risk review.
Explore glucose control, organ function and metabolic care. A group of measurements is a starting point for interpretation.
Connect glucose measurements, everyday needs and continuing review in a defined care plan.
Selected measurements for diabetes and kidney-risk follow-up.
Selected renal, hepatic, electrolyte and metabolic measurements.
Sleep, nutrition and endocrine questions have different pathways. Explore the scope of each before discussing a testing plan.
Understand the sleep complaint, then connect the person with the appropriate evaluation and care team.
Turn a nutritional or functional concern into a practical plan with appropriately qualified support.
Focused tests for symptoms, possible deficiency or endocrine questions.
Begin with the person and their history. These pathways distinguish clinical assessment from testing for a defined indication.
Bring medication review, relevant testing and specialist input into a coherent next step for cognitive symptoms.
A structured plan for people needing continuity between visits and coordination across several care needs.
A specialist-test pathway within an assessment of cognitive symptoms.
Genetic and pharmacogenomic questions require context, a suitable method and careful interpretation. Inspect the records behind each pathway.
Reconcile prescriptions and supplements and consider selected drug–gene information when useful.
Organize the clinical story and identify whether genetics or specialist assessment could clarify an unresolved question.
Selected genetic information linked to a documented medication decision.
Qualified testing matched to phenotype, family history and counseling.
See exploratory measurements alongside their current status. A model or biological-age estimate does not establish a clinical outcome.
An optional question about measurement, repeatability and interpretation—not lifespan prediction.
Define cells, handling and comparators for an interpretable energy-related experiment.
A defined microbiome question with explicit collection and interpretation limits.
No matches in these six perspectives. Search the full directory or try a broader term.
0 questions savedA conversation list, kept in this browser.
An exploration guide, not a test recommendation. Availability and clinical suitability are stated in each directory record.
Test and measurement directory
84 pathways across 6 tracks. Search by question, analyte or family; open any entry for its scope and its limits.
84 pathways
Beyond Reference Laboratory
Useful routine diagnostics. Selected specialty depth. Cross-disciplinary analytical experience brought to questions that deserve a well-defined answer.
Scroll to explode the assembly. Select a part to see what it does and where its limits are.
Presents each capped specimen vial to the system in a defined order, with a documented chain from tube to injection.
Limit: A sample that was mishandled before this point cannot be rescued here.
Drives the mobile phase at a precise, stable flow so that separation and retention times are reproducible.
Limit: Flow drift shifts retention; the method has to be qualified for it.
Holds the separation column at a controlled temperature; this is where compounds separate by how they interact with the stationary phase.
Limit: Two compounds that co-elute are not distinguished by any detector downstream.
Turns the separated compounds into ions so that the analyser can sort them by mass-to-charge ratio.
Limit: Ionisation efficiency depends on the compound and the matrix; it is part of the method.
Sorts and detects ions by mass-to-charge ratio, giving identity and, with calibration, quantity.
Limit: Detection below the quantification limit is real but not a precise concentration.
Our approach
A test answers a question a clinician has asked. The menu is organised by questions, not by instruments.
Routine analysers for routine context; chromatography and mass spectrometry when specificity or sensitivity changes the decision.
Every report carries its method family, quality state and a limit statement. Detectable is not the same as quantifiable.
One specimen, three questions
Chemistry, blood count, lipids, glucose control: the baseline that gives every later question a reference range.
Chromatography and mass spectrometry separate and identify what routine assays summarise; chosen for a defined question.
The same measurement, the same method, over time, with uncertainty shown. Change prompts interpretation; it does not prove cause.
A precise question gives a measurement its purpose. Explore what it means to detect, quantify and distinguish.
Enter the measurement studioMeasurement studio
Every laboratory result is an answer to one of three questions. Is the substance there at all? How much of it is there? And is it this substance, or a neighbour that behaves almost the same? The same instrument answers each differently, and the honest report says which question was actually answered.
A peak at 4.6 min rises to 19 a.u. — above the limit of detection (LOD, 12) but below the limit of quantification (LOQ, 25). The laboratory can say the analyte is present; it cannot yet put a trustworthy number on it.
Synthetic illustration
Every 0.25 min of the 10-minute run (the trace is drawn every 0.05 min). Signal in arbitrary units, 100 full scale. LOD 12, LOQ 25.
| Retention time (min) | Detect | Quantify | Distinguish |
|---|---|---|---|
| 0.00 | 5.2 | 5.2 | 5.2 |
| 0.25 | 6.0 | 6.0 | 6.0 |
| 0.50 | 5.6 | 5.6 | 5.6 |
| 0.75 | 4.8 | 4.8 | 4.8 |
| 1.00 | 4.6 | 4.6 | 4.6 |
| 1.25 | 5.4 | 5.4 | 5.4 |
| 1.50 | 6.4 | 6.4 | 6.4 |
| 1.75 | 6.1 | 6.1 | 6.1 |
| 2.00 | 7.2 | 7.2 | 7.2 |
| 2.25 | 6.7 | 6.7 | 6.7 |
| 2.50 | 5.4 | 5.4 | 5.4 |
| 2.75 | 5.9 | 5.9 | 5.9 |
| 3.00 | 6.2 | 6.2 | 6.2 |
| 3.25 | 4.3 | 4.3 | 4.3 |
| 3.50 | 5.5 | 5.5 | 5.5 |
| 3.75 | 4.9 | 4.9 | 4.9 |
| 4.00 | 5.2 | 5.9 | 5.8 |
| 4.25 | 5.8 | 19.4 | 17.2 |
| 4.50 | 16.0 | 66.9 | 57.7 |
| 4.75 | 13.6 | 57.7 | 49.9 |
| 5.00 | 5.6 | 14.3 | 15.6 |
| 5.25 | 5.9 | 6.3 | 31.0 |
| 5.50 | 4.4 | 4.4 | 52.2 |
| 5.75 | 5.1 | 5.1 | 24.4 |
| 6.00 | 4.9 | 4.9 | 6.5 |
| 6.25 | 4.7 | 4.7 | 4.7 |
| 6.50 | 4.7 | 4.7 | 4.7 |
| 6.75 | 5.5 | 5.5 | 5.5 |
| 7.00 | 6.3 | 6.3 | 6.3 |
| 7.25 | 5.5 | 5.5 | 5.5 |
| 7.50 | 5.5 | 5.5 | 5.5 |
| 7.75 | 7.3 | 7.3 | 7.3 |
| 8.00 | 6.0 | 6.0 | 6.0 |
| 8.25 | 7.0 | 7.0 | 7.0 |
| 8.50 | 5.5 | 5.5 | 5.5 |
| 8.75 | 6.5 | 6.5 | 6.5 |
| 9.00 | 6.3 | 6.3 | 6.3 |
| 9.25 | 5.7 | 5.7 | 5.7 |
| 9.50 | 5.5 | 5.5 | 5.5 |
| 9.75 | 6.5 | 6.5 | 6.5 |
| 10.00 | 5.8 | 5.8 | 5.8 |
| Standard | Retention time (min) | Signal (a.u.) |
|---|---|---|
| cal 1 | 4.60 | 25.8 |
| cal 2 | 4.60 | 50.9 |
| cal 3 | 4.60 | 76.1 |
Instrument families
Each family answers a kind of question. The methods that run on it, the specimen it needs and its limits are documented per method before anything is reported.
| Family | What it measures | Specimen | Status |
|---|---|---|---|
| Routine diagnostic analyzers Targeted clinical tests | Assay-defined chemistries, immunoassay responses and blood-cell measurements | Method-specific serum, plasma, whole blood or urine | Planned |
| Molecular testing & qualified genomics partners Targeted assays; sequencing through a proposed qualified partner where appropriate | Selected pathogen, resistance-associated or human genetic targets | Test-specific swab, urine, blood or validated collection kit | Planned |
| Liquid chromatography & mass spectrometry Targeted quantitative methods; research discovery only when explicitly scoped | Targeted chemical identity or concentration; exploratory features only in a labeled research workflow | Assay-validated extracted human specimens or separately controlled research materials | Planned |
| X-ray diffraction Phase identification and method-supported material questions | Diffraction patterns related to crystalline phases | Prepared mineral, powder or other appropriate solid material | Heritage |
| Wavelength-dispersive X-ray fluorescence Elemental measurement with matrix-appropriate calibration | Element-related characteristic X-ray signals | Method-prepared solids, pellets, beads or other qualified industrial matrices | Heritage |
| Ion chromatography Targeted ionic measurements | Method-defined anions or cations | Qualified industrial/environmental liquids or prepared extracts | Heritage |
| Gas chromatography Targeted applications; detector and method to be verified | Separated chemical responses with detector-dependent identification or quantification | Appropriate industrial liquids, gases or prepared extracts | Heritage |
| Programmed pyrolysis Geochemical and materials questions under a documented method | Responses to controlled heating under a specified analytical program | Prepared geological or other method-qualified industrial materials | Heritage |
| Titration & sample-preparation systems Targeted chemical determinations and preparation for other methods | Method-specific titration endpoints and controlled sample preparation | Appropriate industrial liquids, solids or extracts | Heritage |
Terra heritage
Terra Laboratories brings years of environmental, industrial and food analysis: unusual matrices, trace-level detection, and a habit of stating limits. The clinical laboratory inherits the instruments and the discipline, and keeps the two workflows physically separate.
